Furthermore, while Rheb1 deletion reduced mTORC1 activity in AML cells, additional rapamycin treatment further decreased mTORC1 activity and increased the apoptosis of Rheb1Δ/Δ AML cells. The gene discussed is RHEBP1; the disease is acute myeloid leukemia.